Toronto Dominion Bank Trims Stake in Agilent Technologies, Inc. (NYSE:A)

Toronto Dominion Bank trimmed its position in Agilent Technologies, Inc. (NYSE:A) by 14.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,235 shares of the medical research company’s stock after selling 24,226 shares during the quarter. Toronto Dominion Bank’s holdings in Agilent Technologies were worth $18,697,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gilbert & Cook Inc. increased its holdings in Agilent Technologies by 12.5% during the fourth quarter. Gilbert & Cook Inc. now owns 2,872 shares of the medical research company’s stock valued at $399,000 after buying an additional 320 shares during the period. D.A. Davidson & CO. purchased a new position in shares of Agilent Technologies in the 4th quarter valued at $479,000. Cambridge Investment Research Advisors Inc. raised its position in shares of Agilent Technologies by 6.8% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 12,621 shares of the medical research company’s stock worth $1,755,000 after acquiring an additional 807 shares in the last quarter. Orion Portfolio Solutions LLC lifted its stake in shares of Agilent Technologies by 19.2% during the 4th quarter. Orion Portfolio Solutions LLC now owns 11,033 shares of the medical research company’s stock worth $1,472,000 after purchasing an additional 1,774 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new stake in Agilent Technologies during the fourth quarter valued at about $205,000.

Analyst Upgrades and Downgrades

A has been the topic of a number of recent analyst reports. Bank of America raised their price target on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Evercore ISI raised their target price on shares of Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research note on Thursday, August 22nd. Wells Fargo & Company assumed coverage on Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Finally, Robert W. Baird reduced their target price on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research report on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $141.60.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Agilent Technologies Trading Up 5.2 %

NYSE A opened at $146.74 on Friday. The company has a fifty day moving average of $138.29 and a 200 day moving average of $139.05. The company has a market capitalization of $42.16 billion, a PE ratio of 34.69, a P/E/G ratio of 6.48 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company’s revenue was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.43 earnings per share. Research analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st will be issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.